未登录

K

Koen Degeling

University of Calgary

H指数:13

被引数:500

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Utility of Exome Sequencing: Post-Exome Testing Decision Changes in the Management of Children with Suspected Rare Genetic Disease

全外显子组测序的临床应用：在疑似罕见遗传病儿童的管理中，外显子组检测后的决策变化

Genetics in Medicine

IF6.2

2026-06-110

OAAI

Discrete Event Simulation in R using the ‘Simmer’ Package for Health Economic Modelling: A Tutorial and Illustration in Colon Cancer

使用‘Simmer’包在R中进行离散事件仿真以支持卫生经济建模：结直肠癌教程与实例

Applied Health Economics and Health Policy

IF3.3

2025-06-170

OA

Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2025-01-200

PRE

Exome Sequencing in the Diagnostic Pathway for Suspected Rare Genetic Diseases: Does the Order of Testing Affect its Cost-Effectiveness?

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2024-12-300

PRE

Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia

VALUE IN HEALTH

IF6

2024-10-010

OAAI

Economic Impact of Whole Genome Sequencing and Whole Transcriptome Sequencing Versus Routine Diagnostic Molecular Testing to Stratify Patients with B-Cell Acute Lymphoblastic Leukemia

JOURNAL OF MOLECULAR DIAGNOSTICS

IF3.4

2024-08-010

PRE

Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

JCO CLINICAL CANCER INFORMATICS

IF2.8

2024-07-010

PRE

PRIMCAT: A novel approach to informing health technology assessment decision making in Australia

PRIMCAT: 澳大利亚卫生技术评估决策的一种新方法

ANNALS OF ONCOLOGY

IF65.4

2023-10-010

OAAI

Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer

ANNALS OF ONCOLOGY

IF65.4

2023-10-010

OA

Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2023-08-220

OAAI

Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm

TARGETED ONCOLOGY

IF4

2022-09-058

OAAI

Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer

VALUE IN HEALTH

IF6

2022-01-012

OAAI

Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer

VALUE IN HEALTH

IF6

2021-12-015

OAAI

Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review

EUROPEAN UROLOGY OPEN SCIENCE

IF4.5

2021-05-013

OAAI

Evaluating the resource implications of different service delivery models for offering additional genomic findings

GENETICS IN MEDICINE

IF6.2

2021-04-016

OAAI

Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening

VALUE IN HEALTH

IF6

2021-02-016

OAAI

Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late

在癌症管理中常规实施液体活检: 总是为时过早，直到突然为时已晚

IF3.3

2021-01-1133

OAAI

Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model

HEALTH AND QUALITY OF LIFE OUTCOMES

IF3.4

2020-07-205

OAAI

Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process

MEDICAL DECISION MAKING

IF2.3

2020-05-199

OAAI

PERSONALIZED DISCRETE EVENT SIMULATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FOR FIRST-LINE DOUBLET CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER

VALUE IN HEALTH

IF6

2019-05-010

OAAI